SI1143977T1 - - Google Patents

Info

Publication number
SI1143977T1
SI1143977T1 SI200030683T SI200030683T SI1143977T1 SI 1143977 T1 SI1143977 T1 SI 1143977T1 SI 200030683 T SI200030683 T SI 200030683T SI 200030683 T SI200030683 T SI 200030683T SI 1143977 T1 SI1143977 T1 SI 1143977T1
Authority
SI
Slovenia
Application number
SI200030683T
Inventor
Harold Francis Hodson
Robert Downham
Timothy John Mitchell
Beverley Jane Carr
Christopher Robert Dunk
Richard M J Palmer
Original Assignee
Alizyme Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9900413.7A external-priority patent/GB9900413D0/en
Priority claimed from GBGB9917294.2A external-priority patent/GB9917294D0/en
Application filed by Alizyme Therapeutics Ltd filed Critical Alizyme Therapeutics Ltd
Publication of SI1143977T1 publication Critical patent/SI1143977T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
    • C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI200030683T 1999-01-08 2000-01-06 SI1143977T1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9900413.7A GB9900413D0 (en) 1999-01-08 1999-01-08 Inhibitors
GBGB9917294.2A GB9917294D0 (en) 1999-07-22 1999-07-22 Inhibitors
EP00900082A EP1143977B3 (fr) 1999-01-08 2000-01-06 2-oxy-benzoxazine-4-ones destinees au traitement de l'obesite
PCT/GB2000/000032 WO2000040247A1 (fr) 1999-01-08 2000-01-06 2-amino-4h-3,1-benzoxazine-4-ones destinees au traitement de l'obesite

Publications (1)

Publication Number Publication Date
SI1143977T1 true SI1143977T1 (fr) 2005-08-31

Family

ID=26314965

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030683T SI1143977T1 (fr) 1999-01-08 2000-01-06

Country Status (24)

Country Link
US (4) US6624161B2 (fr)
EP (1) EP1143977B3 (fr)
JP (1) JP3822439B2 (fr)
KR (1) KR100678998B1 (fr)
CN (2) CN1315813C (fr)
AR (1) AR022204A1 (fr)
AT (1) ATE293447T1 (fr)
AU (1) AU765147C (fr)
CA (1) CA2359819C (fr)
CH (1) CH1143977H1 (fr)
DE (1) DE60019555C5 (fr)
DK (1) DK1143977T3 (fr)
ES (1) ES2240052T7 (fr)
HK (2) HK1047588B (fr)
HU (1) HUP0105003A3 (fr)
MX (1) MXPA01006921A (fr)
MY (1) MY122578A (fr)
NO (1) NO333922B1 (fr)
NZ (1) NZ512740A (fr)
PL (1) PL207383B1 (fr)
PT (1) PT1143977E (fr)
RU (1) RU2245331C2 (fr)
SI (1) SI1143977T1 (fr)
WO (1) WO2000040247A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
GB0001572D0 (en) 2000-01-24 2000-03-15 Alizyme Therapeutics Ltd Inhibitors
US6504028B2 (en) * 2000-07-11 2003-01-07 The Procter & Gamble Co. Process for preparing benzoxazin-4-one polymer conjugates
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
NZ531272A (en) 2001-08-30 2006-01-27 Alizyme Therapeutics Ltd Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
CN1620439A (zh) * 2001-12-20 2005-05-25 Osi药物公司 胰脂肪酶抑制剂化合物、其合成方法和应用
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US20060166957A1 (en) * 2003-06-12 2006-07-27 Menachem Rubinstein Methods of treating obesity and related disorders using tellurium selenium compounds
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
WO2006116773A2 (fr) * 2005-04-28 2006-11-02 The Regents Of The University Of California Procedes, compositions et composes de modulation de la lipase de monoacylglycerol, de douleurs et de troubles lies au stress
JP5044398B2 (ja) 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
JP2010254623A (ja) * 2009-04-24 2010-11-11 Takeda Chem Ind Ltd ベンゾオキサジノン化合物の結晶
ES2662710T3 (es) 2010-05-24 2018-04-09 Swedish Oat Fiber Ab Dispersión acuosa que comprende galactolípidos y método de producción de la misma
WO2013092786A1 (fr) 2011-12-23 2013-06-27 Norgine B.V. Compositions comprenant du cetilistat
NL2009995C2 (en) * 2011-12-23 2013-09-18 Norgine Bv Compositions.
DE202012104963U1 (de) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat aufweisende Zusammensetzungen
CN103936687B (zh) * 2014-03-24 2016-03-30 重庆东得医药科技有限公司 一种制备西替利司他的方法
CN104374836A (zh) * 2014-09-19 2015-02-25 安徽安科生物工程（集团）股份有限公司 西替利司他及有关杂质的hplc测定方法
CN105622538B (zh) * 2014-10-27 2019-02-01 中国医学科学院药物研究所 一锅法高收率制备新利司他
CN104341370B (zh) * 2014-11-11 2017-02-22 山东创新药物研发有限公司 一种西替利司他的制备方法
CN105566164A (zh) * 2016-01-06 2016-05-11 北京修正创新药物研究院有限公司 一种新利司他杂质的制备方法
CN105669585A (zh) * 2016-01-06 2016-06-15 北京修正创新药物研究院有限公司 一种新利司他的制备方法
WO2018011676A1 (fr) * 2016-07-11 2018-01-18 Symed Labs Limited Nouveaux procédés de préparation de dérivés de 2-oxy-benzoxazinone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246996C (fr)
US4657893A (en) 1984-05-09 1987-04-14 Syntex (U.S.A.) Inc. 4H-3,1-benzoxazin-4-ones and related compounds and use as enzyme inhibitors
US4745116A (en) 1985-06-25 1988-05-17 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and related compounds and pharmaceutical use
US4665070A (en) * 1985-06-25 1987-05-12 Syntex (U.S.A.) Inc. 2-oxy-4H-3,1-benzoxazin-4-ones and pharmaceutical use
DD246996A1 (de) * 1986-02-26 1987-06-24 Univ Leipzig Verfahren zur herstellung von gegebenenfalls substituierten 2-alkoxy- bzw. 2-aroxy-3,1-benzoxazin-4-onen
CA1309556C (fr) * 1987-06-09 1992-10-27 Masayuki Kokubo Composes 4h-3,1-benzoxazin-4-one et leurs compositions pharmaceutiques utilisees pour l'inhibition de proteases de la serine
US5652237A (en) 1994-09-09 1997-07-29 Warner-Lambert Company 2-substituted-4H-3, 1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r protease for the treatment of inflammatory processes
US5985872A (en) * 1995-05-24 1999-11-16 G.D. Searle & Co. 2-amino-benzoxazinones for the treatment of viral infections
US5776756A (en) * 1995-08-31 1998-07-07 Toyo Hakko Co., Ltd. Fermentation compositions having superoxide dismutating activity and an antihypertensive agent for treatment of constipation each having the superoxide dismutating activity
US6139833A (en) * 1997-08-08 2000-10-31 Lexicon Genetics Incorporated Targeted gene discovery
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6207371B1 (en) * 1996-10-04 2001-03-27 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
CN1280574A (zh) * 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
US6080576A (en) * 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
AR022204A1 (es) * 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.

Also Published As

Publication number Publication date
HUP0105003A3 (en) 2004-11-29
DK1143977T3 (da) 2005-08-15
ES2240052T7 (es) 2013-02-14
US20110065697A1 (en) 2011-03-17
EP1143977B1 (fr) 2005-04-20
RU2245331C2 (ru) 2005-01-27
NO20013381L (no) 2001-09-07
US20030195206A1 (en) 2003-10-16
CA2359819A1 (fr) 2000-07-13
KR20020000542A (ko) 2002-01-05
WO2000040247A1 (fr) 2000-07-13
US7858617B2 (en) 2010-12-28
AU765147B2 (en) 2003-09-11
MY122578A (en) 2006-04-29
PT1143977E (pt) 2005-08-31
NZ512740A (en) 2003-10-31
AR022204A1 (es) 2002-09-04
NO20013381D0 (no) 2001-07-06
WO2000040247A9 (fr) 2002-10-24
KR100678998B1 (ko) 2007-02-07
EP1143977B3 (fr) 2012-10-24
NO333922B1 (no) 2013-10-21
CA2359819C (fr) 2008-08-12
MXPA01006921A (es) 2003-06-04
WO2000040247A8 (fr) 2001-02-15
ES2240052T3 (es) 2005-10-16
HK1047588B (zh) 2007-08-24
AU1884600A (en) 2000-07-24
HK1047588A1 (en) 2003-04-24
CN1915981B (zh) 2011-09-28
HK1103928A1 (en) 2007-12-28
ATE293447T1 (de) 2005-05-15
JP2002534388A (ja) 2002-10-15
HUP0105003A2 (en) 2002-06-29
DE60019555C5 (de) 2009-07-09
US20080161301A1 (en) 2008-07-03
CH1143977H1 (fr) 2007-02-15
US6624161B2 (en) 2003-09-23
EP1143977A1 (fr) 2001-10-17
US7825113B2 (en) 2010-11-02
US20030027821A1 (en) 2003-02-06
PL207383B1 (pl) 2010-12-31
CN1315813C (zh) 2007-05-16
CN1359378A (zh) 2002-07-17
DE60019555D1 (de) 2005-05-25
AU765147C (en) 2007-05-31
CN1915981A (zh) 2007-02-21
JP3822439B2 (ja) 2006-09-20
US8877750B2 (en) 2014-11-04
DE60019555T2 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
BE2018C020I2 (fr)
BE2016C007I2 (fr)
BE2015C057I2 (fr)
BE2015C018I2 (fr)
BE2014C017I2 (fr)
BE2013C051I2 (fr)
BE2013C020I2 (fr)
BE2013C015I2 (fr)
BE2013C001I2 (fr)
BE2012C036I2 (fr)
BE2011C004I2 (fr)
BE2010C011I2 (fr)
BE2008C046I2 (fr)
BE1025464I2 (fr)
BRPI0017527B8 (fr)
BE2008C047I2 (fr)
BRPI0001672A2 (fr)
JP2002518139A5 (fr)
JP2002517938A5 (fr)
BRPI0001542A2 (fr)
JP2002522770A5 (fr)
JP2002527988A5 (fr)
JP2002500024A5 (fr)
BRPI0012675B8 (fr)
BRPI0017522A2 (fr)